UTas ePrintsABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.CDingauthorJXuauthorJLiauthorABT-874, a fully human mAb that blocks the binding of IL-12 and IL-23 to their shared IL-12 receptor beta1, is currently being developed by Abbott Laboratories for the potential treatment of Crohn's disease and psoriasis. The compound is currently in phase III clinical trials for psoriasis and phase II trials for Crohn's disease. ABT-87 was previously being developed for the potential treatment of multiple sclerosis; however, by May 2007, development for this indication was discontinued.320503 Clinical Pharmacology and Therapeutics2008-05Article

Permissions, Copyright and Authorship Statement
I grant the University of Tasmania permission to copy, store and communicate this work I declare that I either own the copyright in the work or I am submitting this work with permission of the copyright owner or under licence from the copyright owner. I declare that the metadata regarding authorship are true and correct and that it complies with the authorship requirements set down in the Joint NHMRC/AVCC Guidelines on Research and Practice.

Clicking on the deposit button indicates your agreement to these terms.